Chronic myelomonocytic leukemia (CMML) and the remaining, less frequent hybrid, mixed,
or overlap myelodysplastic syndromes/myeloproliferative neoplasms (MDSs/MPNs) are …

Patients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently
classified according to the 2017 World Health Organization myelodysplastic syndromes …

Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in
chronic myelomonocytic leukemia (CMML). Due to the lack of CMML‐specific clinical trials …

ASXL1 mutations are found in a spectrum of myeloid malignancies with poor prognosis.
Recently, we reported that Asxl1+/− mice develop myelodysplastic syndrome (MDS) or MDS …

Simple Summary Chronic myelomonocytic leukemia (CMML) is an infrequent disease with
poor prognosis and risk of progression into acute myeloid leukemia (AML). Stem cell …

Abstract Purpose of Review Within the group of the myelodysplastic/myeloproliferative
overlap neoplasms of the adult age, chronic myelomonocytic leukemia (CMML) is …

Outcomes in chronic myelomonocytic leukaemia (CMML) are highly variable and may be
affected by comorbidity. Therefore, prognostic models and comorbidity indices are important …

The efficacy of hematopoietic stem cell transplantation (HSCT) is not well established in
Philadelphia chromosome negative myeloproliferative neoplasms (Ph‐MPNs). Without …

Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with
either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell …

Despite emerging molecular information on chronic myelomonocytic leukemia (CMML),
patient outcome remains unsatisfactory and little is known about the transformation to acute …